The experimental therapy levosimendan has been awarded a U.S. patent covering its use for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to developer Tenax Therapeutics. The United States Patent and Trademark Office (USPTO) issued a notice of allowance to Tenax for a patent for…
News
Pulmonary arterial hypertension (PAH) is associated with high utilization of healthcare resources by patients and with productivity loss, starting years before diagnosis, according to a study in Sweden. “The economic and clinical burden associated with PAH suggests that strategies for earlier diagnosis and more effective treatments are warranted,” researchers…
Dozens of medicines with the potential to treat pulmonary arterial hypertension (PAH) patients ill with COVID-19 were identified through computer analyses of the biological processes shared by both conditions, a pilot study reported. Disease-related features common to COVID-19 and PAH included inflammation, fibrosis (tissue scarring), hypoxia (low oxygen), immune responses,…
Genes associated with both pulmonary arterial hypertension (PAH) and metabolic syndrome have been identified using computer software tools, a study reports. Metabolic syndrome, thought to promote PAH, is a cluster of conditions marked by high blood pressure, elevated blood sugar, excess body fat around the waist, and abnormal cholesterol…
Pregnant women with idiopathic pulmonary arterial hypertension (iPAH) had higher rates of mortality and pregnancy complications than those with other types of PAH or pulmonary hypertension due to left heart disease (LHD-PH), according to a study in China. The prevalence of babies born with low birth weight was also…
The PHenomenal Impact Fund for Global PH Research is accepting research proposals, according to a press release. On its fifth year, Team PHenomenal Hope’s research fund will award up to $50,000 for 12 months for proposals that focus on new concepts in pulmonary hypertension (PH) that have…
Enrollment is now complete in REBUILD, a Phase 3 clinical trial evaluating INOpulse, an investigational treatment for people with pulmonary fibrosis (PF) who are at risk of developing pulmonary hypertension (PH). According to the therapy’s developer, Bellerophon Therapeutics, the trial’s enrollment was completed earlier than expected. As…
Pulmonary hypertension (PH) is estimated to be highly prevalent among people with a history of tuberculosis (TB) who successfully completed treatment, a study in South Africa reports. Further, individuals who were treated for TB more than once had a higher risk of developing PH compared with those who…
Treatment with phosphodiesterase-5 (PDE5) inhibitors can improve blood flow parameters and exercise capacity in people with pulmonary hypertension (PH), according to a new analysis of clinical trial data. “The study found that the reduction in mean PAP [peripheral arterial pressure] was significantly greater in patients receiving PDE5 inhibitors,” the…
The U.S. Food and Drug Administration (FDA) has approved the third generation of Genosyl, Vero Biotech‘s tankless system for nitric oxide delivery, for use as part of care for newborns with pulmonary hypertension. “The continuous innovation of the GENOSYL Delivery System represents our commitment to neonatal intensive care…
The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated, a study suggests. This occurs despite the high frequency of symptoms consistent with CTEPH, underscoring that an appropriate diagnostic work-up of CTEPH is rarely undertaken. The study, “CTEPH: a…
Low activity levels in a small RNA molecule called miR126 may be implicated in vascular remodeling — a hallmark feature of pulmonary hypertension (PH) — in the lungs of chronic obstructive pulmonary disease (COPD) patients regardless of whether or not they also have PH, a study reported. This…
